Hunan Cancer Hospital
Changsha, Hunan, 410013, China
NCT Number: NCT05205226
This study aimed to confirmed that local radiotherapy for residual lesions can significantly prolong the efficacy of chemotherapy combined with immunotherapy in the initial treatment of advanced non-small cell lung cancer.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Changsha, Hunan, 410013, China
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: January 2018 to June 2021
Progression free survival time
Time frame: January 2018 to June 2021
radiotherapy control time
Hunan Province Tumor Hospital
Other
Efficacy and Safety of Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment of Advanced Non-small Cell Lung Cancer: a Retrospective-real World Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05864144
Adenocarcinoma, Adnexal Diseases
Los Angeles, California, United States
View Trial DetailsNCT06863233
Bronchial Neoplasms, Carcinoma, Bronchogenic
Basking Ridge, New Jersey, United States
View Trial DetailsNCT03789604
Bronchial Neoplasms, Carcinoma, Bronchogenic
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT01159288
Bronchial Neoplasms, Carcinoma, Bronchogenic
Villejuif, France
View Trial Details